| 5 | 1/1 | 返回列表 |
| 查看: 2041 | 回復(fù): 7 | |||
| 【有獎交流】積極回復(fù)本帖子,參與交流,就有機(jī)會分得作者 YT21 的 4 個金幣 ,回帖就立即獲得 1 個金幣,每人有 1 次機(jī)會 | |||
| 當(dāng)前只顯示滿足指定條件的回帖,點擊這里查看本話題的所有回帖 | |||
[交流]
Hackensack Meridian School of Medicine(新澤西州)張毅實驗室招聘三名博士后
|
|||
|
Three postdoctoral positions are available in Dr. Yi Zhang’s lab at Center for Discovery & Innovation, Hackensack Meridian School of Medicine (New Jersey). Dr. Zhang introduced for the first time the concept of alloantigen-sensitized stem cell memory T cells in sustaining alloimmunity. This concept of T cell stemness stimulates cancer immunotherapy field to develop novel strategies for improving the efficacy of cancer therapy. The Zhang lab has also discovered that Ezh2 plays multiple roles in the regulation of T cell stemness and T cell immunity. Currently, the Zhang lab studies epigenetic therapy, focusing on immune regulation and tumor immune-sensitization. Ongoing research projects investigate: 1) the molecular pathways that mediate Ezh2 actions in T cells; 2) epigenetic therapy to sensitize tumor to T cell immunity; and 3) novel genetic and pharmacologic approaches to program T cells for improving the efficacy of cancer immunotherapy. Advanced technologies, including drug-screening, CRISPR-editing and scRNA-sequencing analysis, are leveraged to facilitate these studies. The ideal candidate should have PhD degree or equivalent, with at least one 1st author publication. Background in immunology, cancer biology and molecular genetics is preferred. The candidate should be highly motivated and able to work independently under the PI’s supervision, with strong scientific ethnic. Please submit application electronically with CV, statement of interest and the names/ emails of three referees to: Dr. Yi Zhang (Professor), Email: yi.zhang@temple.edu. Hackensack Meridian School of Medicine(新澤西州)發(fā)現(xiàn)與創(chuàng)新中心的 Yi Zhang 博士實驗室提供三個博士后職位。張博士首次創(chuàng)立了干細(xì)胞樣記憶T細(xì)胞維持同種異體抗原免疫反應(yīng)的概念。這一概念引導(dǎo)了癌癥免疫治療領(lǐng)域開發(fā)提高癌癥治療功效的新策略。張實驗室還發(fā)現(xiàn)Ezh2在調(diào)節(jié)T細(xì)胞干性和T細(xì)胞免疫中發(fā)揮多重作用。 目前,張實驗室研究表觀遺傳療法,重點是免疫調(diào)節(jié)和腫瘤免疫致敏。正在進(jìn)行的項目研究:1) 在 T 細(xì)胞中介導(dǎo) Ezh2 作用的分子途徑; 2) 表觀遺傳療法增強(qiáng)腫瘤對 T 細(xì)胞免疫敏感; 3) 新的遺傳和藥理學(xué)方法編程 T 細(xì)胞以提高癌癥免疫治療的功效。多項先進(jìn)的技術(shù),包括藥物篩選、CRISPR 編輯和 scRNA 測序分析,被用于促進(jìn)這些研究。 理想的候選人應(yīng)具有博士學(xué)位或同等學(xué)歷,至少有一篇第一作者發(fā)表。有免疫學(xué)、癌癥生物學(xué)和分子遺傳學(xué)背景者優(yōu)先。候選人應(yīng)具有高度的積極性,能夠在PI的指導(dǎo)下獨立工作,具有強(qiáng)烈的科學(xué)素養(yǎng)。請將申請電子版連同簡歷、意向書和三位推薦人的姓名/電子郵件提交至:張毅博士,電子郵件:yi.zhang@temple.edu。 張毅教授的個人簡介網(wǎng)址:https://medicine.temple.edu/yi-zhang (今年9月份正式搬去Hackensack Meridian School of Medicine,新實驗室的網(wǎng)頁尚未準(zhǔn)備好) |
» 搶金幣啦!回帖就可以得到:
+2/864
+1/86
+2/52
+1/50
+1/40
+1/36
+1/34
+1/32
+1/20
+1/10
+1/10
+1/9
+1/6
+1/4
+1/4
+1/1
+1/1
+1/1
+1/1
+1/1
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 286 +3 | ksncj 2026-03-04 | 3/150 |
|
|---|---|---|---|---|
|
[考研] 307求調(diào)劑 +3 | xuyuan111 2026-03-04 | 4/200 |
|
|
[考研] 085701環(huán)境工程 求調(diào)劑 +6 | xiiiia 2026-03-04 | 6/300 |
|
|
[考研] 材料專碩346求調(diào)劑 +3 | 旺一下 2026-03-04 | 3/150 |
|
|
[考研] 301求調(diào)劑 +3 | 李LJR 2026-03-04 | 3/150 |
|
|
[考研] 085601 材料工程 320 +6 | 和樂瑤 2026-03-03 | 6/300 |
|
|
[考研] 材料工程269求調(diào)劑 +7 | 白刺玫 2026-03-02 | 7/350 |
|
|
[考研] 291求調(diào)劑 +4 | Afy123456 2026-03-03 | 7/350 |
|
|
[考研] 290求調(diào)劑 +9 | ErMiao1020 2026-03-02 | 9/450 |
|
|
[考研] 材料學(xué)碩318求調(diào)劑 +15 | February_Feb 2026-03-01 | 17/850 |
|
|
[考研]
材料工程專碩283求調(diào)劑
5+8
|
,!? 2026-03-02 | 10/500 |
|
|
[考研] 338求調(diào)劑 +5 | 18162027187 2026-03-02 | 6/300 |
|
|
[考研] 求調(diào)劑 +11 | yunziaaaaa 2026-03-01 | 13/650 |
|
|
[考研] 0856材料調(diào)劑 +5 | 沿岸有貝殼OUC 2026-03-02 | 5/250 |
|
|
[考研] 285求調(diào)劑 +9 | 滿頭大汗的學(xué)生 2026-02-28 | 9/450 |
|
|
[考研] 材料與化工328求調(diào)劑 +3 | 。,。,。,。i 2026-03-02 | 3/150 |
|
|
[考研] 279求調(diào)劑 +3 | dua1 2026-03-01 | 4/200 |
|
|
[基金申請]
|
Doma 2026-03-01 | 7/350 |
|
|
[碩博家園] 博士自薦 +7 | 科研狗111 2026-02-26 | 11/550 |
|
|
[考研] 化工299分求調(diào)劑 一志愿985落榜 +5 | 嘻嘻(*^ω^*) 2026-03-01 | 5/250 |
|